Human antibodies constitute a fast-growing therapeutic class. Evaluate Pharma (February 2016) expects that 10 of the top-20 pharmaceutical products by 2020 will be antibodies accounting for 53% of sales.
According to The Antibody Society (October 2016), 65 therapeutic antibodies are now approved, 62 of which were generated in vivo by animals and only three of which were generated in vitro with phase display technologies. The same data demonstrates that older technologies such as murine and chimeric antibodies are rapidly being replaced by humanized and fully human antibodies.
In 2015 the total therapeutic antibody market was estimated at $80 billion, the predominant portion of which is coming from current OmniAb partners such as Genentech, Roche and Janssen. The market is expected to grow to about $150 billion in 2020 with the top-10 products accounting for $66 billion (44%). Ligand’s objective is to make OmniAb available to as many pharmaceutical and biotech companies as possible in this growing therapeutic antibody market.
According to Reichert (November 2015), close to 500 antibodies were in various stages of clinical development in the US in late 2015. The number of therapeutic antibody candidates in US Phase 3 clinical development is now over 50, a doubling over the past five years.